These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12871368)

  • 21. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
    Bredberg E; Andersson TB; Frison L; Thuresson A; Johansson S; Eriksson-Lepkowska M; Larsson M; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):765-77. PubMed ID: 12846597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
    Halperin JL
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers.
    Johansson LC; Andersson M; Fager G; Gustafsson D; Eriksson UG
    Clin Pharmacokinet; 2003; 42(5):475-84. PubMed ID: 12739985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation.
    Schützer KM; Wall U; Lönnerstedt C; Ohlsson L; Teng R; Sarich TC; Eriksson UG
    Curr Med Res Opin; 2004 Mar; 20(3):325-31. PubMed ID: 15025841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
    Eriksson UG; Johansson S; Attman PO; Mulec H; Frison L; Fager G; Samuelsson O
    Clin Pharmacokinet; 2003; 42(8):743-53. PubMed ID: 12846595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
    Elg M; Gustafsson D; Deinum J
    Thromb Haemost; 1997 Oct; 78(4):1286-92. PubMed ID: 9364999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
    Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
    Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers.
    Dorani H; Schützer KM; Sarich TC; Wall U; Logren U; Ohlsson L; Eriksson UG
    Eur J Clin Pharmacol; 2007 Jun; 63(6):571-81. PubMed ID: 17387462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model.
    Harenberg J; Zokai K; Piazolo L; Fenyvesi T; Jörg I
    Semin Thromb Hemost; 2002 Aug; 28(4):379-82. PubMed ID: 12244485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men.
    Wernevik LC; Nyström P; Johnsson G; Nakanishi T; Eriksson UG
    Clin Pharmacokinet; 2006; 45(1):77-84. PubMed ID: 16430312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.
    Klement P; Carlsson S; Rak J; Liao P; Vlasin M; Stafford A; Johnston M; Weitz JI
    J Thromb Haemost; 2003 Mar; 1(3):587-94. PubMed ID: 12871470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
    Eriksson UG; Bredberg U; Gislén K; Johansson LC; Frison L; Ahnoff M; Gustafsson D
    Eur J Clin Pharmacol; 2003 May; 59(1):35-43. PubMed ID: 12743672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists.
    Wolzt M; Eriksson UG; Gouya G; Leuchten N; Kapiotis S; Elg M; Schützer KM; Zetterstrand S; Holmberg M; Wåhlander K
    Thromb Res; 2012 Apr; 129(4):e83-91. PubMed ID: 21925716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.
    Sarich TC; Teng R; Peters GR; Wollbratt M; Homolka R; Svensson M; Eriksson UG
    Clin Pharmacokinet; 2003; 42(5):485-92. PubMed ID: 12739986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects.
    Wolzt M; Wollbratt M; Svensson M; Wåhlander K; Grind M; Eriksson UG
    Eur J Clin Pharmacol; 2003 Oct; 59(7):537-43. PubMed ID: 12955372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.
    Sarich TC; Eriksson UG; Mattsson C; Wolzt M; Frison L; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):300-5. PubMed ID: 11858491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S; Johansson K; Kjaer M; Elg M
    Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.
    Meyer BJ; Badimon JJ; Chesebro JH; Fallon JT; Fuster V; Badimon L
    Circulation; 1998 Feb; 97(7):681-5. PubMed ID: 9495304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat.
    Carlsson S; Elg M
    Blood Coagul Fibrinolysis; 2005 Jun; 16(4):245-9. PubMed ID: 15870543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.